Max Robotics — Global Service Robot Directory + US Certification

About

Tommaso Grassi is a gynecologic oncology researcher whose work focuses on optimizing surgical management and prognostic assessment for endometrial cancer. His major contributions center on two key areas: the safety and cost-effectiveness of shifting hysterectomy from inpatient to outpatient settings, and the prognostic significance of lymphovascular space invasion (LVSI) in early-stage disease. His 2021 study on the national trend toward outpatient hysterectomy for endometrial cancer, cited 17 times, demonstrated that this transition is safe, reduces healthcare costs, and is enabled by minimally invasive techniques and enhanced recovery protocols. This work has informed clinical practice and healthcare policy. More recently, his SLYMEC II study (2025) provided critical overall survival data confirming that LVSI is an independent predictor of worse outcomes in apparent early-stage endometrioid endometrial cancer, even when accounting for other risk factors. This finding helps refine risk stratification and guide adjuvant therapy decisions. Grassi’s research bridges surgical innovation and prognostic precision, directly impacting patient care and resource allocation in gynecologic oncology.